Loading quotes...
Forecast
The analysts' average price target is €8.04 (+390.24%). The median is €8.04 (+390.24%).
| Buy |
10 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -35.37M | 81.44% |
| EBITDA | -32.98M | 88.26% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €116.81M |
Number of shares | 71.62M |
52-week high/low | €3.32 - €1.48 |
| Dividends | No |
Beta | 0.94 |
P/E ratio | -1.16 |
PEG ratio | 0.13 |
P/B ratio | 0.55 |
P/S ratio | 0.00 |
Company profile
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Name | NKARTA INC. DL -,0001 |
| CEO | Paul J. Hastings |
| Headquarters | South San Francisco,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 07/10/2020 |
| Employees | 106 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | NKTX |
